Sector is indicated for the treatment of heart failure (NYHA class II-IV) in patients with systolic dysfunction. Sector has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ACE) inhibitor therapy.